VRTX Jan 2025 260.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:58PM EDT. Market open.
| Previous close | 2.5500 |
| Open | 2.5500 |
| Bid | 1.0000 |
| Ask | 3.2000 |
| Strike | 260.00 |
| Expiry date | 2025-01-17 |
| Day's range | 2.5500 - 2.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | 112 |
ZacksVertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
Business WireVertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
BOSTON, April 18, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548).
ZacksVertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Vertex Pharmaceuticals (VRTX) closed at $394.17 in the latest trading session, marking a -0.8% move from the prior day.
© 2024 Yahoo. All rights reserved.